hat
Lè Sibutramine te premye formul, li te gen entansyon pou itilize kòm yon depresè. Malerezman, dwòg la pa t anpil siksè nan trete depresyon. Dezavantaj sa a, sepandan, yon benediksyon nan degize pou pasyan ki twò gwo ak obèz. Pasyan deprime te note ke dwòg la redwi konsomasyon kalori ak diminye apeti, konsa ede yo pèdi pwa. Nan 1997, Sibutramine te apwouve pa FDA pou itilize kòm yon medikaman pèdi pwa nan peyi Etazini.
eng
When Sibutramine was first formulated, it was intended for use as an antidepressant. Unfortunately, the drug wasn’t very successful in treating depression. This drawback was, however, a blessing in disguise for overweight and obese patients. Depressed patients noted that the drug reduced caloric intake and decreased appetite, thus helped them lose weight. In 1997, Sibutramine was approved by FDA for use as a weight loss medication in the United States.